Full Press Release Details
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab).
BIIB
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
Key Takeaway: Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
Price reaction · baseline $139.31 (2025-08-22 close) · clean, no other BIIB news in the window
day 0 close · peak
-2.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis